Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals announced that Dr. Simon Pimstone, the CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:30 pm ET. Investors can access the presentation through a webcast on the company's website, with a replay available afterward. Xenon is focused on developing innovative therapeutics for neurological disorders, particularly epilepsy, through its robust clinical-stage pipeline.
Xenon Pharmaceuticals reported steady progress in its neurology clinical programs despite COVID-19 disruptions. The company anticipates significant clinical milestones over the next year, including Phase 3 trials for XEN496 in KCNQ2 developmental and epileptic encephalopathy and top-line data from the XEN1101 trial. Financially, as of March 31, 2020, Xenon had $229.7 million in cash, with total revenue of $7.1 million for Q1 2020. The net loss for the quarter was $7.5 million, an improvement from $11.3 million in Q1 2019, reflecting operational efficiency amidst rising clinical development costs.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) plans to report its first quarter 2020 financial and operating results on May 21, 2020, after U.S. markets close. Following this, a conference call and audio webcast will be held at 4:30 PM ET to discuss the results and provide a corporate update. Interested participants can join by dialing (855) 779-9075 or (631) 485-4866 for international callers, using conference ID 8385218. The webcast will be available for replay for 30 days on Xenon's website.